These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
459 related articles for article (PubMed ID: 18836488)
1. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488 [TBL] [Abstract][Full Text] [Related]
2. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054 [TBL] [Abstract][Full Text] [Related]
3. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046 [TBL] [Abstract][Full Text] [Related]
4. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Styczynski J; Einsele H; Gil L; Ljungman P Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376 [TBL] [Abstract][Full Text] [Related]
5. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695 [TBL] [Abstract][Full Text] [Related]
6. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556 [TBL] [Abstract][Full Text] [Related]
7. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Buyck HC; Ball S; Junagade P; Marsh J; Chakrabarti S Bone Marrow Transplant; 2009 May; 43(10):813-6. PubMed ID: 19104495 [TBL] [Abstract][Full Text] [Related]
8. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965 [TBL] [Abstract][Full Text] [Related]
9. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S; Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985 [TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506 [TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897 [TBL] [Abstract][Full Text] [Related]
12. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702 [TBL] [Abstract][Full Text] [Related]
13. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207 [TBL] [Abstract][Full Text] [Related]
14. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation]. Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188 [TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of donor lymphocyte infusion to treat Epstein-Barr virus associated lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation]. Xu LP; Liu DH; Liu KY; Chen H; Han W; Wang Y; Wang J; Shi HX; Huang XJ Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):955-8. PubMed ID: 21211211 [TBL] [Abstract][Full Text] [Related]
16. Management and outcome of liver recipients with post-transplant lymphoproliferative disease. Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611 [TBL] [Abstract][Full Text] [Related]
17. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438 [TBL] [Abstract][Full Text] [Related]
18. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Ahmad I; Cau NV; Kwan J; Maaroufi Y; Meuleman N; Aoun M; Lewalle P; Martiat P; Crokaert F; Bron D Transplantation; 2009 Apr; 87(8):1240-5. PubMed ID: 19384173 [TBL] [Abstract][Full Text] [Related]
19. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716 [TBL] [Abstract][Full Text] [Related]
20. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]